Akeso Inc. has received approval from the National Medical Products Administration to initiate Phase II clinical trials for its bispecific antibody AK139 in China. The trials will cover seven indications, including chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis. AK139 is the first clinical-stage antibody to target both IL-4Rα and ST2 pathways, and the Phase II studies aim to evaluate its therapeutic potential in respiratory and autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN85713) on February 11, 2026, and is solely responsible for the information contained therein.